A 36 month, Multicenter, Randomized, Phase 3, Double-blind, Placebo-Controlled, Study to Assess the Effect of isradipine on Patients with early Parkinson’s disease (PD) symptoms.

HS 2014-1309
Movement disorders, Parkinsons
Neal Hermanowicz, MD
UC Irvine
As Parkinson’s disease progresses in a patient, symptoms such as shaking, stiffness and slowness of movement increase over time. This makes it difficult for a patient to function independently.

Adding isradipine for Parkinson’s disease may slow the progression of the disease by improving both motor and cognitive function. The results of this study may help doctors learn more about isradipine and its benefits to patients with a new diagnosis of PD.

To qualify for this study, you must be: 

  • At least 30 years of age at the time of your PD diagnosis
  • Diagnosed with PD less than 3 years ago
  • Not have received brain surgery for PD
  • Not have received dopaminergic therapy within 60 days of 2nd visit or 3 consecutive months in the past
  • Not have atypical Parkinsonism
Please note this is only a partial list of eligibility, as other exclusions apply.
This study includes 12 in-person visits and four follow-up phone calls throughout the study. The study takes about 31 hours over a period of 36 months.

You may not directly benefit from participating in this study. However your participation may be beneficial to others by providing information that is useful to our understanding of the study drug and its use in PD. PD naturally worsens over time. The study drug may slow, have no effect on, or accelerate the expected worsening in the progression of PD.

Another benefit of participating in this study includes frequent medical evaluations and close monitoring of your health status by a doctor who specializes in PD. However, there is no guarantee that you will benefit from being in this research.

Taking part in this study may or may not make your health better. While researchers hope the drug being studied, isradipine, will be more effective than other treatments, there is no proof of that yet.

This study will help researchers learn more about isradipine’s effect on early PD symptoms and it is hoped that this information will help in the treatment of future patients with conditions like yours.

You will receive a check for $20, at specified time points over the course of the study to help pay for travel costs to and from your visits. There are 12 visits. Total compensation for participation in the entire study is $240.
Steady: Isradipine
Drug therapy
Katrina Samson